A randomized controlled Phase Ib trial of the malaria vaccine candidate GMZ2 in African children

Sabine Bélard, Saadou Issifou, Aurore B Hounkpatin, Frieder Schaumburg, Ulysse Ateba Ngoa, Meral Esen, Rolf Fendel, Pablo Martinez de Salazar, Raymund E Mürbeth, Paul Milligan, Nathalie Imbault, Egeruan Babatunde Imoukhuede, Michael Theisen, Søren Jepsen, Ramadhani A Noor, Brenda Okech, Peter G Kremsner, Benjamin Mordmüller

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

61 Citationer (Scopus)

Abstract

GMZ2 is a fusion protein of Plasmodium falciparum merozoite surface protein 3 (MSP3) and glutamate rich protein (GLURP) that mediates an immune response against the blood stage of the parasite. Two previous phase I clinical trials, one in naïve European adults and one in malaria-exposed Gabonese adults showed that GMZ2 was well tolerated and immunogenic. Here, we present data on safety and immunogenicity of GMZ2 in one to five year old Gabonese children, a target population for future malaria vaccine efficacy trials.
OriginalsprogEngelsk
TidsskriftP L o S One
Vol/bind6
Udgave nummer7
Sider (fra-til)e22525
ISSN1932-6203
DOI
StatusUdgivet - 2011

Citationsformater